Skip to content

Plasma Hydrogen Sulfide as a Biomarker for Alzheimer's Disease and Related Dementias

Plasma Hydrogen Sulfide as a Biomarker for Alzheimer's Disease and Related Dementias

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05060848
Enrollment
100
Registered
2021-09-29
Start date
2021-04-01
Completion date
2027-05-31
Last updated
2023-03-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer Disease, Dementia

Keywords

biomarker, vascular disease, sex differences, race differences

Brief summary

Hydrogen sulfide is a signaling molecule that is important for vascular health. Because vascular factors such as hypertension and high cholesterol are risk factors for Alzheimer's disease and related dementias, we hypothesize that hydrogen sulfide plays an important role in brain health as well. We will compare blood levels of hydrogen sulfide across groups of people with and without dementia. We will also look at the relationship between hydrogen sulfide, cognitive dysfunction and measures of brain microvascular disease examine the contribution of hydrogen sulfide to cognitive decline. Our goal is to identify a biomarker of vascular dysfunction in dementia.

Detailed description

We have described hydrogen sulfide (H2S), a signaling molecule important in vascular homeostasis, as a biomarker of cardiovascular disease. There is accumulating evidence that vascular factors such as hypertension, hypercholesterolemia, and type 2 diabetes are associated with increased risk of Alzheimer's disease and related dementias (ADRD). Furthermore, in the brain, H2S acts as a neurotransmitter/second messenger produced following nerve excitation. It also modulates N-methyl-D-aspartate (NMDA) receptors during long term potentiation for memory consolidation. Three biochemical forms of reactive sulfur pools exist: free H2S, acid-labile (e.g. iron-sulfur clusters) and bound sulfide (e.g. persulfides, polysulfides). We hypothesize that H2S becomes dysregulated in ADRD, where vascular and cognitive functions are linked. We will use analytical biochemical methods to measure plasma H2S and its metabolites, and 3T MRI to evaluate indicators of microvascular disease in ADRD. We will compare H2S levels in people with and without cognitive dysfunction consistent with ADRD, and determine the specificity and sensitivity of H2S indistinguishing people with and without cognitive dysfunction. In addition, because previous studies report differences in the incidence and prevalence of ADRD by race and sex, we will compare outcomes across these groups as well. Finally, we will examine the potentially mediating role of H2S in the relationship between cognitive function and microvascular disease.

Interventions

None listed

Sponsors

Louisiana State University Health Sciences Center Shreveport
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
55 Years to 100 Years
Healthy volunteers
Yes

Inclusion criteria

* All participants must be aged \>55 years with English as the 1⁰ language, with stable permitted medications for \<4 weeks, geriatric depression scale score \<6, visual and auditory acuity adequate to perform tests, and history of education excluding developmental cognitive abnormalities.

Exclusion criteria

*

Design outcomes

Primary

MeasureTime frameDescription
Cognitive OutcomesProspective, single measurementADAS Cog score
Imaging OutcomesProspective, single measurementMRI based brain volume measures, FLAIR lesion volume
Blood OutcomesProspective, single measurementPlasma Hydrogen sulfide including metabolites: free, acid labile, bound and total sulfides.

Secondary

MeasureTime frameDescription
Demographic DataProspective, single measurementAge, Race, Sex, Socioeconomic status

Other

MeasureTime frameDescription
Comorbidity Data (covariates)Prospective, single measurementBP, weight, Hx of smoking, diabetes, hypertension, elevated cholesterol

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026